基础起始,正当其时重庆ppt课件.pptVIP

下载本文档

7
0
约4.41万字
约 38页
2018-06-20 发布于四川
举报
版权申诉

基础起始,正当其时重庆ppt课件.ppt

1、本文档共38页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

基础起始,正当其时重庆ppt课件

Subject: Fasting Plasma Glucose 6 to 12 Weeks After Starting Insulin Glargine Predicts Success in Reaching A1c≤7.0% at Weeks 24-28 37% 35% 随机,开放,平行实验,纳入756名未用过胰岛素的超重T2DM患者，HbA1c7.5%－10%。患者在原有OADs基础上随机接受睡前注射来得时或NPH治疗6个月，目标FBG 5.5mmol/L。这些患者用一种或两种口服降糖药治疗（磺脲类、二甲双胍、噻唑烷二酮单药或联合治疗），既往未曾用胰岛素治疗，A1c在7.5%-10%。患者在原有口服药物的基础上随机接受睡前注射来得时或NPH。研究结束时，两组患者的血糖水平都得到控制，两组平均A1c均为6.94%。有57%的患者达到了A1C?7%的目标。但是两组的低血糖的情况如何呢 ? The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. Source Oregon Health and Science University, Portland, Oregon 97201, USA. riddlem@ohsu.edu Abstract OBJECTIVE: To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c). RESEARCH DESIGN AND METHODS: In a randomized, open-label, parallel, 24-week multicenter trial, 756 overweight men and women with inadequate glycemic control (HbA(1c) 7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG) or=100 mg/dl (5.5 mmol/l). Outcome measures were FPG, HbA(1c), hypoglycemia, and percentage of patients reaching HbA(1c) or=7% without documented nocturnal hypoglycemia. RESULTS: Mean FPG at end point was similar with glargine and NPH (117 vs. 120 mg/dl [6.5 vs. 6.7 mmol/l]), as was HbA(1c) (6.96 vs. 6.97%). A majority of patients ( approximately 60%) attained HbA(1c) or=7% with each insulin type. However, nearly 25% more patients attained this without documented nocturnal hypoglycemia (or=72 mg/dl [4.0 mmol/l]) with glargine (33.2 vs. 26.7%, P 0.05). Moreover, rates of other categories of symptomatic hypoglycemia were 21-48% lower with glargine. CONCLUSIONS: Systematically titrating bedtime basal insulin added to oral therapy can safely ac